Purpose. Human papillomavirus (HPV) E6/E7 mRNA is a more specific marker for cervical lesion screening than HPV DNA. Here, we aimed to develop a new one-step multiplex reverse transcript real-time PCR (MRT-PCR) to detect E6/E7 mRNA from 14 high-risk HPV (hrHPV) genotypes.
INTRODUCTION
Cervical cancer is the most prevalent malignant gynaecological tumour in developing countries and is second only to breast cancer worldwide. It is a significant threat to women's health, and the incidence in the younger population continues probe (Tabto increase [1] . High-risk human papillomavirus (hrHPV) infection has been proven to be the major cause of cervical cancer. About 95 % of cervical cancer cases are associated with continuous hrHPV infection; persistent hrHPV infection is the most important factor and a necessary condition in cervical cancer occurrence and development [2] .
HPV DNA has been widely used as a target for cervical lesion screening in recent years. It is detectable from the very early stages of infection, before cytological abnormalities occur. Routine HPV DNA testing in susceptible populations supports the early diagnosis and treatment of cervical lesions, reducing the onset of cervical cancer greatly. However, HPV infection is transient in the majority of cases, with only about 10 % of patients suffering a persistent infection. HPV DNA detection reports all HPV infections, but its effectiveness for reporting disease progression, e.g. the transcription level of viral oncogenes or whether the virus is in an active phase, is limited [3] .
HrHPV E6/E7 mRNA and the corresponding E6/E7 oncoproteins are emerging targets for the in vitro monitoring of HPV infection. E6/E7 proteins break the regulation of host cell proliferation by degrading the tumour suppressor proteins p53 and pRb [4] [5] [6] [7] [8] . In early stages, viral E6/E7 gene expression is restrained; however, as the infection progresses, hrHPV can increase E6/E7 expression by integrating its genome into the host genomic DNA [9, 10] . This process may promote the proliferation of the host cell, and increases the risk of malignancy. The cervical intraepithelial neoplasia (CIN), which is considered to be the premalignant transformation of cervical surface squamous cells, is a result of E6/E7 overexpression. Compared to HPV DNA, E6/E7 oncogene mRNA expression is a promising biomarker for the population screening of hrHPV infection [11] [12] [13] .
In this study we developed a simple, reliable and efficient hrHPV E6/E7 mRNA detection method based on multiplex reverse transcript real-time PCR (MRT-PCR) technology. Liquid-based thin-layer cytology test (TCT) One hundred and sixty-six HPV-positive LBC samples were processed using the ThinPrep2000 (Hologic) automated slide preparation system followed by microscopic examination. The results were classified according to the Bethesda system (TBS): normal À no atypical squamous cells of undetermined significance (ASCUS) observed; low-grade squamous intraepithelial lesion (LSIL); high-grade squamous intraepithelial lesion (HSIL); cervical squamous cell carcinoma (SCC); adenocarcinoma (AC).
Colposcopy examination
After being diagnosed as HPV-positive, all 166 potential patients went through a multiple-site colposcopy followed by pathology inspection within 48 h. Based on the severity of the cervical lesions, cases were divided into five histology grades: normal or inflamed cervical epithelium; mild dysplasia or abnormal cell growth confined to the basal 1/3 of the epithelium (CIN I); moderate dysplasia confined to the basal 2/3 of the epithelium (CIN II); severe dysplasia spanning more than 2/3 of the epithelium, sometimes also referred as cervical carcinoma in situ (CIN III); and invasive carcinoma. CIN I is equivalent to LSIL, while CIN II and CIN III are both considered to be HSIL.
E6/E7 mRNA control material preparation HPV E6/E7 control materials were prepared as described by Jie Huang et al. [14] . The 14 types of hrHPV whole genome purchased from NIFDC were used as the primary template. The prepared mRNA was verified by sequencing.
HPV E6/E7 mRNA detection by bDNA signal amplification assay The Quantivirus HPV E6/E7 RNA 3.0 assay (bDNA) kit (DiaCarta, CA, USA) was used in this experiment for comparison. The Quantivirus HPV E6/E7 RNA 3.0 assay was a sandwich nucleic acid hybridization procedure for the direct quantitation of HPV RNA in residual (LBC) samples without RNA purification and RT-PCR. It is able to detect the E6/E7 mRNA of 14 high-risk subtypes of HPV, including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. The assay was shown to be linear from 615 to 7 690 000 IU ml À1 [15] . The 166 LBC samples were processed and tested following the manufacturer's instructions. Briefly, 10 ml of each sample was transferred to a centrifuge tube and centrifuged at 12 000 g for 5 min, the supernatant was discarded, 200 µl lysis mixture and 5 µl proteinase K were added to the centrifuge tube and mixed thoroughly, and this was followed by incubation at 65 C for 1 h. Then 50 µl lysis working reagent was added to each tube before 100 µl preamplifier probe working reagent was added to each well of the capture plate. The capture plate was sealed and incubated at 55 C for 40 min. Then100 µl amplifier probeworking reagent was added to each well of the capture plate, which was sealed and incubated at 55 C for 40 min. After this, 100 µl label probe working reagent was added to each well of the capture plate, which was sealed again and incubated at 50 C for 40 min. Then 100 µl substrate working reagent was added to each well of the capture plate, which was sealed a third time and incubated at 46 C for 20 min. Finally, after the plate was removed from the incubator, it was read by the System DiaCarta QuantiVirus Reader.
HPV E6/E7mRNA detection by one-step MRT-PCR RNA was extracted from 166 HPV-positive LBC samples using the TIANamp Virus DNA/RNA kit as per the manufacturer's instructions, with the exception that 50 µl DEPC water was used for RNA elution in the final step. The purified RNA was used as a template in one-step MRT-PCR HPV E6/E7 mRNA analysis and the results were compared with those from a bDNA signal amplification assay to assess the accuracy and sensitivity of the former. The clinical value of the developed method was evaluated according to the results of cytological and histological tests. The detailed RT-PCR procedure is as follows. Nine microlitres of RNA template was mixed with 10 µl 2ÂDNase I buffer and 1 u DNase I (Takara), and the mixture was incubated in 37 C for 30 min to remove DNA. The MRT-PCR reaction mix contained 2 µl DNase I-treated RNA, 4 µl 5ÂPCR buffer (Takara), 4 mM MgCl 2 , 0.2 mM dNTP (Takara), 0.1 µM of each primer and 0.05 µM of each probe (Table 1) , 0.5 u reverse transcriptase (Takara), 1 u hot-start Taq polymerase and RNase-free water to make up a total volume of 40 µl. The MRT-PCR was carried out on LightCycler480 (Roche) 
GAPDH-F TTTTCGGGCCAGCTTTCAG GAPDH-R TTTCACACGTGCAATCAAAGG GAPDH-P CTGACTGAGTTAGAT CY5
GAPDH-F, GAPDH-R and GAPDH-P are the primers and probes of the internal control gene. To avoid false negatives due to the degradation of mRNA, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. In this experiment, Ct 38 was set as the positive threshold. This threshold is also applicable to the internal control; a Ct of the internal control >38 indicates an invalid test.
The sensitivity and specificity of MRT-PCR RNA was extracted from 14 types of hrHPV mRNA control material using a TIANamp virus DNA/RNA kit and quantified using a Bio-Rad Droplet Digital PCR system (BioRad). The RNA with a quantified copy number was then 10-fold diluted with TE buffer containing 10 ng ml À1 human genomic DNA to obtain a set of serial dilutions ranging from 1Â10 8 to 10 copies µl À1 . Then 0.2 µl of each dilution was used as a template in MRT-PCR as described above. Each dilution was tested 20 times. A CT 38 was set as the positive threshold. For quality control, a Ct of the internal control >38 indicated an invalid test. The limit of detection (LOD) of the assay was defined as the lowest concentration (target gene copy number per reaction) for which !95 % of test runs gave positive results. To evaluate the specificity of the MRT-PCR assay, DNA was purified from N. gonorrhoeae-, C. albicans-, E. coli-, S. aureus-and HSVII-, TP-, UU-and M. hominis-positive LBC samples using a TIANamp virus DNA/RNA kit following the manufacturer's instructions, except that the DNase I digestion step was skipped. HPV6, 11, 26, HPV E6/E7 mRNA detection by bDNA signal amplification and one-step MRT-PCR The E6/E7 mRNA in 166 LBC samples were tested using the Quantivirus HPV E6/E7 RNA 3.0 assay (bDNA) kit and one-step MRT-PCR simultaneously. The MRT-PCR detected 58 E6/E7 mRNA-positive cases, making the total positive rate 34.9 %. In contrast, the bDNA signal amplification method detected 50 (30.1 %) E6/E7 mRNA-positive cases ( Table 3 ). The corresponding rate was calculated using SPSS 19.0 statistical software ( The E6/E7 mRNA detection method was compared with the histopathological method. In the 50 HPV E6/E7 mRNA-positive cases detected by bDNA signal amplification, there were 2 (2.4 %) normal cases, 33 (50.8 %) CIN I cases, 11 (78.6 %) CIN II cases, 2 (100 %) CIN III cases and 2 (100 %) SCC cases ( Table 4 ). Given that CIN II or more severe lesions are considered to be positive, the sensitivity of bDNA signal amplification in clinical application was 83.3 %, with a specificity of 76.4 %, while the positive predictive value was 30 % and the negative predictive value was 97.4 %. Meanwhile, in the MRT-PCR test results, the 58 HPV E6/E7 mRNA-positive samples included 4 (4.8 %) normal cases, 38 (58.4 %) CIN I cases, 12 (85.7 %) CIN II cases, 2 (100 %) CIN III and 2 (100 %) SCC cases. Under the same criterion as described above, the sensitivity, specificity, positive predictive value and negative predictive value of the MRT-PCR method in clinical application were 88.9, 71.6, 27.6 and 98.1 %, respectively. Analysis of the sensitivity and specificity of MRT-PCR According to the results for the lower detection limit assay, the sensitivity of MRT-PCR on HPV16, 18, 31, 33, 35, 39, 45, 66 and 68 is 20 copies per reaction, while for HPV51, 52, 56, 59 and 58 it is 200 copies per reaction. In the specificity test, none of the 18 low-risk HPV types or other pathogens that are commonly found in the female genital tract (N. gonorrhoeae, C. albicans, E. coli, S. aureus, HSVII, TP, UU and M. hominis) were detected by MRT-PCR, suggesting good specificity.
DISCUSSION
Cervical cancer screening by high-risk HPV DNA detection has been widely used in women because hrHPV infection is the greatest risk factor for cervical cancer [16] [17] [18] . The major drawback of this method is the lack of clinical specificity. As a matter of fact, the majority of HPV infections are cleared by the host immune system in a short period before the onset of cervical lesion [19] . To reduce overdiagnosis and overtreatment, it is important to improve the specificity of the screening technology. In previous studies, hrHPV E6 and E7 oncoproteins and the corresponding E6/E7 mRNA have been found to be persistent in human cervical carcinoma tissue, while the elevated E6/E7 gene expression is responsible for the carcinogenesis of host cells [13, 20] . The role of the E7 protein is to promote tumour growth by inactivating members of the retinoblastoma protein (pRb) tumour suppressor family, while the E6 protein binds and inactivates p53, which is a tumour suppressor protein in the host cell that acts to down-regulate cell growth and promote apoptosis when irreparable DNA damage occurs [21] . High concentrations of E6 and E7 protein cause the immortalization of the host cell and eventually cancer. Compared with HPV DNA, HPV E6/E7 mRNA is a target for more precise screening, allowing cervical lesion diagnosis with better resolution in clinical practice. By reducing the false positives caused by transient hrHPV infection, unnecessary colposcope tests could also be reduced. Furthermore, in some cases missing the L1 region in the HPV genome after its integration into the host DNA may cause negative results in HPV DNA detection, which is avoidable by using HPV E6/ E7 mRNA detection instead [22] . [25] .
In our study we have developed a single-step multiplex reverse transcript real-time PCR for E6/E7 mRNA of 14 hrHPV types. The advantage of our method is that the mRNA of 14 hrHPV types are detected in a single tube, making it more practicable in routine use. The primers and probes were originally designed and optimized to minimize the chance of dimer formation for high-multiplicity PCR. In our actual experiment, we found that the primer and probe set mentioned by Lindh et al. dis not cooperate well with our multiplex PCR system; the observed analytical sensitivity for HPV 18, 31, 35 and 45 was 1000 copies per reaction, while for HPV 52, 56, 58 and 59 it was only 5000 copies per reaction. Our single-step hrHPV E6/E7 mRNA detection method is adaptable to various fluorescent quantitative PCR instrument models. All 14 hrHPV E6/E7 mRNA are detected in one tube within 3 h. The manipulation procedure is relatively simple and more practicable for clinical laboratory application. In this study, E6/E7 mRNA in 166 hrHPV-positive LBC samples were detected by the bDNA signal amplification method and MRT-PCR in parallel, and the concordance rate of the MRT-PCR method to the bDNA method was: positive: 100 %; negative: 93.33 %; overall: 95.18 %, with kappa=0.8858 (95 % CI: 0.809-0.962), suggesting good consistency between the results obtained using the two methods. When the results were compared with the histopathology results from the same 166 samples, more cervical lesion-positive samples (CIN II or above) were detected by one-step MRT-PCR than bDNA signal amplification (88.9 vs 83.3 %). Futhermore, the overall trend observed in this study was the positive rate of hrHPV E6/E7 mRNA increasing with the severity of cervical lesion, which further proved that the progression of cervical carcinoma is closely related to the elevated transcription level of the HPV E6/E7 gene, especially at stages where the severity of the cervical lesion is !CIN II. This result is also consistent with what has been reported previously [26] [27] [28] . In conclusion, we have developed a simple, fast, universally applicable, sensitive and highly specific method for hrHPV E6/E7 mRNA detection that is reliable for cervical lesion screening and of potential value in future clinical applications.
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